Trends in Pharmacological Sciences 1996: Vol 17 Index

21 Pages·1996·4.9 MB·English

trends in
PHARMACOLOGICAL
SCIENCES
ae MOD.6 [ Ol O) OLS) [O7.8 Ba.) Oi 8 OI oh
Author Index
Subject Index
Books Reviewed Index
1996
Vol 17
Issues 1—12
ISSN 0165 6147
Trends in Pharmacological Sciences
Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 ILA
Tel: [phone]
Fax: [phone]
[phone]
E-mail: TIPS @elsevier.co.uk
Advisory Editorial Board P. M. Beart, Monash University, Melbourne, Australia
N. J. M. Birdall, National Institute of Medical Research, London, UK
N. G. Bowery, University of Birmingham, Birmingham, UK
J.N. Crawley, National Institute of Mental Health, Bethesda, MD, USA
A.C. Cuello, MCGill University, Montréal, Canada
J.R. Fozard, Sandoz, Basel, Switzerland
B. B. Fredholm, Karolinska Institute, Stockholm, Sweden
T. Godfraind, Université Catholique de Louvain, Brussels, Belgium
M. Lazdunski, Université de Nice, Valbonne, France
P. Leff, Astra, Loughborough, UK
L. Limbird, Vanderbilt University, Nashville, TN, USA
J. Meldolesi, Instituto H. San Raffaele, Milan, Italy
M. Otsuka, Tokyo Medical & Dental University, Tokyo, Japan
C. P. Page, King’s College, London, UK
U. Quast, University of Tiibingen, Germany
M. M. Reidenberg, Cornell Medical Center, New York, NY, USA
R. Ruffolo, Jr, SmithKline Beecham, King of Prussia, PA, USA
C. D. Strader, Schering-Plough Research Institute, Kenilworth, NJ, USA
H. Timmerman, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Z. G. Wang, Institute of Basic Medical Sciences, Beijing, China
Editor Deborah Girdlestone
Assistant Editors lan K. Wright and Annette Mead
Editorial Administrator Claire Robson
Publisher Peter Desmond
Copyright © 1997 Elsevier Science Ltd. All rights reserved.
This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd.
Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system
or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without
the prior written permission of the Publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.
Author Index
BR Book Review
L Letter
SR Software Review
A Chapman, I. D., Contract research F
Alexander, S. P. and Ford, A. P. D. W., pharmacology 60 Fauchere, A. L., see Boutin, J. A.
Purines 96 385 Choi, Y-B., see Sucher, N. J. 348 Ferguson, D. and Christopher, N.,
Anderson, G. P., Resolution of chronic Choi, Y-B., see Lipton, S. A. (L) 186 Ferguson and Christopher reply (L)
inflammation by therapeutic induction Christopher, N., see Ferguson, D.(L) 315 Ferguson, D. and Christopher, N.,
of apoptosis 438 Christopher, N., see Ferguson, D. 161 Urinary bladder function and drug
Argilés, J. M. and Lopez-Soriano, F. J., Chuang, T. T., Iacovelli, L., Sallese, M. and development
The ubiquitin-dependent proteolytic De Blasi, A., G protein-coupled Fernandez-Salguero, P., see McLeod, H.
pathway in skeletal muscle: its role in receptors: heterologous regulation of (L)
pathological states homologous desensitization and its Feuerstein, G., see Wang, X.
Arner, P., see Lafontan, M. implications 416 Fina, P., see Corsi, M.
Arribas, S., see McGrath, J. C. Coleman, R. A., Johnson, M., Nials, A. T. Flower, R. J. et al., The William Harvey
Ashton, C. H., see Young, A. H. (L) and Vardey, C. J., Exosites: their current Research Institute: 10th anniversary
Awobuluyi, M., see Sucher, N. J. status, and their relevance to the Ford, A. P. D. W., see Alexander, S. P.
duration of action of long-acting Fox, S. H. and Brotchie, J. M., New
B B,-adrenoceptor agonists treatments for movement disorders?
Balla, T., see Hunyady, L. 135 Connolly, G. P., Simmonds, H. A. and Fozard, J. R., see Miiller, T.
Barnard, E. A., The transmitter-gated Duley, J. A., Pyrimidines and CNS Fredholm, B. B., see Ongini, E.
channels: a range of receptor types and regulation (L) Fredholm, B. B., see Jacobson, K. A.
structures 305 Cooper, D. M. F., Signal Transduction Freeman, J., Careers in pharmaceutical
Barnes, N. M., see Parker, R. M. C. 95 Protocols (BR) clinical development
Bayne, M. L., see Murgolo, N. J. 389 Corsi, M., Fina, P. and Trist, D. G., Frohman, M. A., see Morris, A. J.
Beani, L., see Simonato, M. 410 Co-agonism in drug-receptor Frélich, J. C., Careers in pharmacology:
Beart, J. J., see Reid, P. M. 205 interaction: illustrated by the NMDA the German perspective
Behan, D. P., see Chalmers, D. T. 166 receptors
Ben-Ari, Y., see Gozlan, H. (L) 187 Costa, E. and Guidotti, A., G
Bentley, K. R., see Parker, R. M. C. 95 Benzodiazepines on trial: a research Gargalidis Moudanos, C., see Parini, A.
Bertrand, C. and Geppetti, P., Tachykinin strategy for their rehabilitation George, C. F. and Paterson, J. W.,
and kinin receptor antagonists: Cox, H. M., see Playford, R. J. Festschrift in honour of Professor Sir
therapeutic perspectives in allergic Cusack, B., see Le, F. Colin Dollery 317
airway disease 255 Geppetti, P., see Bertrand, C. 255
Birdsall, N., see Lazareno, S. (L) 443 D Giembycz, M. A., Phosphodiesterase 4
Black, J. W., TiPS on identity 121 Daly, C. J., see McGrath, J. C. 393 and tolerance to 8,-adrenoceptor
Bolard, J., see Hartsel, S. C. 445 Daly, J. W., see Jacobson, K. A. 108 agonists in asthma 331
Bond, R. A. and Girdlestone, D., Darlington, C. L., see Smith, P. F. 421 Girdlestone, D., Emerging Drugs (BR) 337
Romancing receptor research at Verona Davies, H. J., A Guide to Clinical Drug Girdlestone, D., TiPS Advisory Editorial
classification meeting 85 Research (BR) 463 Board 2
Boutin, J. A. and Fauchere, A. L., Davis, T. P., see Konkoy, C. S. 288 Girdlestone, D. and Page, C. P., What
Combinatorial peptide synthesis: De Blasi, A., see Chuang, T. T. 416 to do with a degree in pharmacology? 31
statistical evaluation of peptide de Souza, E. B., see Chalmers, D. T. 166 Girdlestone, D., Educational and
distribution 8 Demolombe, S., see Escande, D. 273 industrial contacts in the UK 82
Bowery, N. G., see Malcangio, M. 457 Devlin, J. M., Pharmacology education in Girdlestone, D., Essentials of Pharmacology
Brink, C., see Gorenne, I. 342 the USA: I. The role of undergraduate (BR) 203
Brotchie, J. M., see Fox, S. H. 339 programmes Girdlestone, D., International Union of
Brown, J. E., see Murgolo, N. J. 389 Duley, J. A., see Connolly, G. P. (L) Pharmacology: member Societies 67
Bruns, R. F., Conformational induction Girdlestone, D., IUPHAR
versus conformational selection: evidence E subcommittees /P at Humphrey /
from allosteric enhai.cers (L) 189 Elbadawi, A., see Kuchel, G. A. (L) Leslie Benet 29
Buckel, P., Recombinant proteins for Elliot, J. D., see Warner, T. D. Girdlestone, D., Loomis’s Essentials of
therapy 450 Elmhirst, D. N., Working fom home: Toxicology (BR) 203
freelance medical writing Girdlestone, D., Pharmaceutical companies
el Engebrecht, J., see Morris, A. J. in the UK 77
Candura, S. M., see Tonini, M. (L) 314 Engels, P., see Miiller, T. Girdlestone, D., Pharmaceutical Research
Catt, K. J., see Hunyady, L. 135 Escande, D. and Demolombe, S., and Manufacturers of America 79
Chalmers, D. T., Lovenberg, T. W., ATP-binding cassette proteins as Girdlestone, D., see Bond, R. A. 85
Grigoriadis, D. E., Behan, D. P. and targets for drug discovery Girdlestone, D., The TiPS Advisory
de Souza, E. B., Corticotrophin-releasing Esposito, E., An indirect action for Editorial Board 123
factor receptors: from molecular fluoxetine on the dopamine Girdlestone, D., The TiPS Advisory
cloning to drug design 166 neurotransmitter system (L) Editorial Board 124
Girdlestone, D., The top TiPS articles 123 Kohama, K., Ye, L-H., Hayakawa, K. and Milligan, G., Marshall, F. and Rees, S., G16
Girdlestone, D., The Year’s Drug News 1995 Okagaki, T., Myosin light chain kinase: as a universal G protein adapter:
(BR) 203 an actin-binding protein that regulates implications for agonist screening
Godfraind, T., The celebration of 200 an ATP-dependent interaction with strategies 235
issues of TiPS 122 myosin 284 Modin, A., see Lundberg, J. M. 301
Godfraind, T., The International Union Konkoy, C. S. and Davis, T. P., Mohr, K., see Kostenis, E. (L) 443
of Pharmacology welcomes clinical Ectoenzymes as sites of peptide Mohr, K., see Kostenis, E. 280
pharmacologists to Latin America regulation 288 Morris, A. J., Engebrecht, J. and
Godson, C., see Reppert, S. M. 100 Koroshetz, W. J. and Moskowitz, M. A., Frohman, M. A., Structure and
Gonzalez, F. J., see McLeod, H. L Emerging treatments for stroke in regulation of phospholipase D 182
(L) 107 humans 227 Morton, I. K. M., Understanding
Gorenne, I., Norel, X. and Brink, C., Kostenis, E. and Mohr, K., Kostenis and Medications: What the Label Doesn't Tell
Cysteinyl leukotriene receptors in the Mohr reply (L) 443 You (BR) 173
human lung: what’s new? 342 Kostenis, E. and Mohr, K., Two-point Moskowitz, M. A., see Koroshetz, W.J. 227
Gozlan, H. and Ben-Ari, Y., NMDA and kinetic experiments to quantify allosteric Miller, T., Engels, P. and Fozard, J. R.,
GABA, receptors, NO and redox effects on radioligand dissociation 280 Subtypes of the type 4 cAMP
modulation (L) 187 Krieger, C., Lanius, R. A., Pelech, S. L. and phosphodiesterases: structure,
Graham, R. M., Neubig, R. and Shaw, C. A., Amyotrophic lateral regulation and selective inhibition 294
Lynch, K. R., «,-Adrenoceptors take sclerosis: the involvement of intracellular Munro, S., Cannabinoid Receptors (BR) 201
centre stage at Nashville meeting Ca** and protein kinase C 114 Murgolo, N. J., Brown, J. E., Bayne, M. L.
Grigoriadis, D. E., see Chalmers, D. T. Kuchel, G. A., Resnick, N. M. and and Strader, C. D., Presenilin mutation
Guidotti, A., see Costa, E. Elbadawi, A., The ageing bladder in in Alzheimer’s disease: molecular
urinary tract disorders (L) 314 models suggest a potential functional
H Kuhar, M. J. and Pilotte, N. S., locus 389
Halliday, A. J., Careers in the media: Neurochemical changes in cocaine
life one step away from research 65 withdrawal 260 N
Hartig, P. R., Humphrey, P. P., Hoyer, D. Neubig, R., see Graham, R. M.
and Martin, A. G. R., Alignment of L Ney, U. M., Pharmacology and
receptor nomenclature with the human Lafontan, M. and Arner, P., Application of biotechnology: a career in clinical
genome: classification of 5-HT,, and in situ microdialysis to measure development
5-HT,p receptor subtypes 103 metabolic and vascular responses in Nials, A. T., see Coleman, R. A.
Hartsel, S. C. and Bolard, J., adipose tissue 309 Nicholas, A. P., Hokfelt, T. and
Amphotericin B: new life for an Lambert, D. G., see Smart, D. 264 Pieribone, V. A., The distribution and
old drug 445 Lanier, S. M., see Parini, A. 13 significance of CNS adrenoceptors
Hayakawa, K., see Kohama, K. 284 Lanius, R. A., see Krieger, C. 114 examined with in situ hybridization 245
Hernandez, J. and Ribeiro, J. A., Excitatory Lazareno, S. and Birdsall, N., Quantitation Norel, X., see Gorenne, I. 342
actions of adenosine on ventricular of allosteric interactions (L) 443
automaticity 141 Le, F., Cusack, B. and Richelson, E., The Oo
Hoflack, J., Guidebook on Molecular neurotensin receptor: is there more than Ohlstein, E. H., see Warner, T. D. 177
Modelling in Drug Design (BR) 463 one subtype? 1 Ohnishi, A., see Ishizaki, T. 45
Hokfelt, T., see Nicholas, A. P. 245 Liberini, P., Valerio, A., Memo, M. and Okagaki, T., see Kohama, K. 284
Hollenberg, M. D., Protease-mediated Spano, P., Lewy-body dementia and Ongini, E. and Fredholm, B. B.,
signalling: new paradigms for cell responsiveness to cholinesterase Pharmacology of adenosine A},
regulation and drug development 5 inhibitors: a paradigm for heterogeneity receptors 364
Holmén, J., Successful Scientific Writing of Alzheimer’s disease? 155
(BR) 202 Lipton, S. A., Choi, Y-B., Sucher, N. J., P
Holsboer, F., see Trapp, T. 145 Pan, Z-H. and Stamler, J. S., Redox state, Page, C. P., see Girdlestone, D. 31
Hoyer, D., see Hartig, P. R. 103 NMDA receptors and NO-related species Pan, Z-H., see Lipton, S. A. (L) 186
Hughes, I. E., Teaching pharmacology in (L) 186 Parini, A., Gargalidis Moudanos, C.,
the UK: a view from academia 32 Lipton, S. A., see Sucher, N. J. 348 Pizzinat, N. and Lanier, S. M., The
Humphrey, P. P., see Hartig, P. R. 103 Lépez-Soriano, F. J., see Argilés, J. M. 223 elusive family of imidazoline binding
Hunyady, L., Balla, T. and Catt, K. J., Lovenberg, T. W., see Chalmers, D.T. 166 sites 13
The ligand binding site of the Lundberg, J. M., Modin, A. and Parker, R. M. C., Bentley, K. R. and
angiotensin AT, receptor 135 Malmstrém, R. E., Recent developments Barnes, N. M., Allosteric modulation of
with neuropeptide Y receptor 5-HT; receptors: focus on alcohols
I antagonists 301 and anaesthetic agents 95
lacovelli, L., see Chuang, T. T. 416 Lynch, K. R., see Graham, R. M. 90 Pasternak, G. W. and Standifer, K. M.,
Ishizaki, T. and Ohnishi, A., Careers in Pasternak and Standifer reply (L) 257
clinical pharmacology: present status M Paterson, J. W., see George, C. F. 317
and future academic perspectives in Malcangio, M. and Bowery, N. G., GABA Pelech, S. L., see Krieger, C. 114
Japan 45 and its receptors in the spinal cord 457 Perkins, J. P., Pharmacology education in
Mallet, J., The TiPS/TINS Lecture. the USA: II. The role of graduate
J Catecholamines: from gene regulation to programmes 42
Jacobson, K. A., Fredholm, B. B., neuropsychiatric disorders 129 Perkins, R., Companion to Pharmacology.
Daly, J. W. and von Lubitz, D. K. J. E., Malmstrém, R. E., see Lundberg, J.M. 301 A Study Guide For Self-assessment and
Adenosine receptor ligands: Mann, J., Mushrooms: Poisons and Panaceas Revision (BR) 174
differences with acute versus chronic (BR) 173 Philippu, A., see Singewald, N. 356
treatment Marley, P. D., see Reid, P. M. 205 Pieribone, V. A., see Nicholas, A. P. 245
Johnson, M., see Coleman, R. A. Marshall, F., see Milligan, G. 235 Pietri-Rouxel, F., see Strosberg, A.D. 373
Johnson, T. D., Modulation of channel Martin, A. G. R., see Hartig, P. R. 103 Pilotte, N.S., see Kuhar, M. J. 260
function by polyamines Martin, W., The agonists and the ecstasy: Pizzinat, N., see Parini, A. 13
Johnston, G. A. R., GABA, receptors: life as an academic pharmacologist 51 Playford, R. J. and Cox, H. M., Peptide YY
relatively simple transmitter-gated ion Martin, Y. C., Chemometric Methods in and neuropeptide Y: two peptides
channels? 319 Molecular Design (BR) 28 intimately involved in electrolyte
Jones, R. L., see Wise, H. ib g McGrath, J. C., Arribas, S. and Daly, C. J., homeostasis 436
Jones, T., Supporting the industry: the Fluorescent ligands for the study of Power, C. A. and Wells, T. N. C.,
Association of the British receptors 393 Cloning and characterization of human
Pharmaceutical Industry 50 McLeod, H. L., Fernandez-Salguero, P. and chemokine receptors 209
Kenakin, T., Receptor conformational Gonzalez, F. J., McLeod et al. reply
induction versus selection: all part of (L) 107 R
the same energy landscape (L) 190 Memo, M., see Liberini, P. 155 Rees, S., see Milligan, G. 235
Rees, S. A., Academic research: K+ Smart, D. and Lambert, D. G., The Traynor, J. R., The Pharmacology of Opioid
channels and an affair of the heart 53 stimulatory effects of opioids and their Peptides (BR) =
Reid, P. M., Beart, J. J. and Marley, P. D., possible role in the development of Trist, D. G., see Corsi, M. 220
NO problems down-under 205 tolerance 264 Tuk, B. and van Oostenbruggen, M. F.,
Reppert, S. M., Weaver, D. R. and Smith, P. F. and Darlington, C. L., Recent Solving inconsistencies in the analysis
Godson, C., Melatonin receptors step advances in the pharmacology of the of receptor-ligand interactions 403
into the light: cloning and vestibulo-ocular reflex system 421
classification of subtypes 100 Spano, P., see Liberini, P. 155 vV
Resnick, N. M., see Kuchel,G. A.(L) 314 Stamler, J. S., see Lipton, S. A. (L) 186 Valerio, A., see Liberini, P. 155
Ribeiro, J. A., see Hernandez, J. 141 Standifer, K. M., see Pasternak, G. W. van Oostenbruggen, M. F., see Tuk, B. 403
Richelson, E., see Le, F. 1 (L) 217 Vardey, C. J., see Coleman, R. A. 324
Roberts, P. J., see Toms, N. J. 429 Stanford, S. C., Stanford replies (L) 401 von Lubitz, D. K. J. E., see Jacobson, K. A.
Rosenkilde, M. M., see Schwartz, T. W. Stanford, S. C., Prozac: panacea or 108
(L) 347 puzzle? 150
Rosenkilde, M. M., see Schwartz, T. W. 213 Staton, P. C., see Toms, N. J. 429 WwW
Ruffolo, R. R., see Wang, X. 276 Strader, C. D., see Murgolo, N. J. 389 Walker, M. J. A., Pharmacology and
Strange, P. G., 7TM receptors: ‘locks’ and education in Canada: a personal
S ‘keys’? (L) 346 perspective 36
Sallese, M., see Chuang, T. T. 416 Strange, P. G., The energetics of ligand Wang, X., Ruffolo, R. R. and Feuerstein, G.,
Salt, T. E., see Toms, N. J. 429 binding at catecholamine receptors 238 mRNA differential display: application
Salvemini, D., Preclinical industrial Strosberg, A. D. and Pietri-Rouxel, F., in the discovery of novel
research 58 Function and regulation of the pharmacological targets 276
Schwartz, T. W. and Rosenkilde, M. M., B-adrenoceptor 373 Warner, T. D., Elliot, J. D. and Ohlstein, E. H.,
Is there a ‘lock’ for all agonist ‘keys’ Sucher, N. J., Awobuluyi, M., Choi, Y-B. California dreamin’ ‘bout endothelin:
in 7TM receptors? 213 and Lipton, S. A., NMDA receptors: emerging new therapeutics
Schwartz, T. W. and Rosenkilde, M. M., from genes to channels 348 Weaver, D. R., see Reppert, S. M.
Schwartz and Rosenkilde reply Sucher, N. J., see Lipton, S. A. (L) 186 Webb, D. J., Life as an academic clinical
(L) pharmacologist
Seale, J. P., Careers in pharmacology: T Wells, T. N. C., see Power, C. A.
an Australian academic perspective 34 Toms, N. J., Roberts, P. J., Salt, T. E. and Wise, H. and Jones, R. L., Focus on
Shaw, C. A., see Krieger, C. 114 Staton, P. C., Latest eruptions in prostacyclin and its novel mimetics
Simmonds, H. A., see Connolly, G. P. metabotropic glutamate receptors 429 Wollemann, M., Orphan receptor or
(L) 106 Tonini, M. and Candura, S. M., 5-HT, k,-opioid receptor? (L) 217
Simonato, M. and Beani, L., The receptor agonists and bladder Wright, I. K., Antimicrobial Chemotherapy
neurochemistry of morphine addiction disorders (L) 314 (3rd edn) (BR) 28
in the neocortex 410 Trapp, T. and Holsboer, F.,
Singewald, N. and Philippu, A., Heterodimerization between ¥
Involvement of biogenic amines and mineralocorticoid and glucocorticoid Ye, L-H., see Kohama, K. 284
amino acids in the central regulation of receptors increases the functional Young, A. H. and Ashton, C. H.,
cardiovascular homeostasis 356 diversity of corticosteroid action 145 Pharmacokinetics of fluoxetine (L) 400

Subject Index
compiled by Laurence Errington
A vestibulo—ocular reflex and 424-425 Adrenocorticotrophic hormone-releasing
A127722 178, 179, 180 nomenclature 246-247 factor, see Corticotrophin-releasing factor
ABC (ATP-binding cassette) proteins a-Adrenoceptors Aequorin (A. victoria green fluorescent
273-275 bladder/ urethra 162 protein) 236, 237
Academics in pharmacology antagonists and their effects 164 Affective disorders, see Anxiety; Depression
personal experiences of 51-57 fluorescent ligand studies 395, 396, 399 Ageing bladder and urinary tract
pharmacology education and careers and morphine administration and its disorders 314-315
the views of effects 413 Agonists (in general)
in Australia 34-36 a,-Adrenoceptors affinity, see Receptors
in UK 32-34 adenosine and 142-143 binding sites, classification and
research, see research CNS, localization 245-246, 251 importance of molecular biology in
N-Acetyl-aspartylglutamate 431 subtypes 246 determining 87-88
Acetylcholine a,-Adrenoceptors 90-94 co-agonism 220-222
morphine effects on release 412, 413 antagonist affinities 91 conformational induction as route
vestibulo—ocular reflex and 423, 426 CNS for receptor activation by 189-191
Acetylcholine receptors localization 247, 251 efficacy 86
fluorescent ligand studies 394 movement disorders and 254 conformational matching in
muscarinic, see Muscarinic drug design and therapeutics with, modelling of 88
acetylcholine receptors advances difficulties in estimating 220-222
vestibulo-ocular reflex and 426 function G protein-coupled receptors,
Acetyltransferase transporter, vesicular, physiology, advances screening system 235-237
gene 132 signalling pathways and effector of seven transmembrane domain
Acidosis, ubiquitin-dependent systems receptors, ‘lock’ for agonist
proteolysis in skeletal muscle in 225 structure ‘keys’ 213-216, 346-347 (L)
ACTH-releasing factor, see subtypes 90-91, 246-247 stabilizing multiple active states of
Corticotrophin-releasing factor targeting and trafficking 93 receptors 190-191
Actin-binding proteins 284-287 B-Adrenoceptors see also specific receptors
myosin light chain kinase as 284-287 adenosine and 142 Airway
other 285-286 antagonists in heart failure 419-420 cysteinyl leukotriene receptors 342-345
Adenosine CNS kinin and tachykinin receptor
catecholamines and, interactions 143-144 localization 247-248, 251 antagonists and allergic disease
ventricular automaticity and movement disorders and 253-254 of 255-259
excitatory actions of 141-144 fluorescent ligand studies 394, 399 pharmacology, contract research 60-61
Adenosine receptors morphine administration and its B-Alanine, 5-fluorouracil competing
108-113, 364-372, 385-386 effects 413 with uracil for 107 (L)
A, 108-113, 385-386 pharmacological characteristics of Alcohols and 5-HT; receptors 95-97
Ava 108-113, 364-372, 386 different types Alimentary tract, see Gastrointestinal tract
A,, compared with 368 subtypes Allergic disease
antagonists 367-371 B,-Adrenoceptors airway, kinin and tachykinin receptor
distribution 365 pharmacological characteristics antagonists and 255-259
pharmacology 367-371 salmeterol duration of action at phosphodiesterase upregulation in
Asp 368, 386 B,-Adrenoceptors 334-335
Ae 111, 387 agonists Allergic inflammation, see Inflammation
ligands, acute vs. chronic effects in asthma, phosphodiesterase 4 Allosteric modulation
of 108-113 and tolerance to 331-336 conformational induction as route for
therapeutic perspectives 111-113, 371, 388 long-acting, exosites and duration receptor activation evidenced
ventricular automaticity and 142-144 of action of 324-330 y 189-191
Adenoviral-encoded gene therapy, antagonists, reversal of long-acting of GABA action 192, 193
Parkinson’s disease 134 agonist action by 326-327 partial 197
Adipose tissue mutant 329, 346 (L) 5-HT; receptors 95-97
metabolism pharmacological characteristics 374 radioligand dissociation caused by,
B3-adrenoceptors and 379 serine residues and ligand binding two-point kinetic experiments
in situ microdialysis in measurement activity of 346 (L) quantifying 280-283, 443-444 (L)
of 309-313 B,-Adrenoceptors 373-381 Alpha-adrenoceptors, see Adrenoceptors
vascular response, in situ microdialysis agonists 374, 375 Alprazolam, cognition deficits induced
in measurement of 309-313 pathology 379 by 198-199
ADP-ribosylation factor family of G pharmacological properties 373-375 Alzheimer’s disease 155-160
proteins and phospholipase D activity physiological role 377-379 corticotrophin-releasing factor and 170
182-183 regulation of expression and heterogeneity 155-160
Adrenaline neurones, central, function 380 Lewy-body dementia and,
adrenoceptor subtypes and 249-252 salmeterol duration of action at 328 differentiation 156, 157, 158-159
Adrenoceptors 244-255 structure-function relationships 375-377 presenilin mutations in 389-393
central therapeutic aspects 379-380 protein kinase C and 119, 120
localization 245-255 Adrenocortical steroids, see Corticosteroid Amiloride, structure 14
Amines, biogenic imidazenil as prototype of new Birdsall, Nigel J.M. 124
cardiovascular system and role of generation of 199 Bladder 161-165, 314-316 (L)
356-361 metabotropic Glu receptor agents as 435 ageing 161
morphine administration interfering Antidepressants, tricyclic, in disorders 162-165, 314-316 (L)
with neurochemistry of 410-412 incontinence 163 drug therapy 162-165
see also specific (types of) amines Anti-epileptic drugs, imidazenil as types 163
Amino acids prototype of new generation of 199 function 161
cardiovascular regulation involving 359 Antifungal, amphotericin B as 445-446 innervation 161, 162
excitatory, see Excitatory amino acids Antihypertensives, neuropeptide Y, outfl/o outwle t
inhibitory, receptors, vestibulo—ocular receptor agonists as 437 obstruction 163
reflex and 424 Anti-inflammatory agents in stroke 229, 231 resistance, altering 164, 314 (L)
cis-4-Aminocrotonic acid (CACA) and Antimicrobials sphincter, see Urethral sphincter
GABA¢ receptors 319, 321 amphotericin B as 447 Blood
Aminopeptidase A 290-291 Antimicrobial chemotherapy 28 (BR) flow in adipose tissue, in situ
Aminopeptidase N 290 Antinociception and GABA 460 microdialysis in measurement of
3-Aminopropyl(methyl)phosphinic acid Antiviral activity of amphotericinB 446 pressure, brain structures involved in
(3-APMPA) Anxiety and corticotrophin-releasing control 358-359
as GABA, antagonist 321 factor 169 BMS182874 179
structure 322 Anxiolytic drugs, imidazenil as prototype BMY45778
3-Aminopropylphosphinic acid (3-APPA) of new generation of actions 20
as GABA, antagonist 321 Apoptosis 438-442 structure 18
structure 322 chronic inflammation resolved via BODIPY in fluorescent ligand studies
3-Aminopropylphosphonic acid (3-APA) therapeutic induction of 438-442 394-399
as GABA, antagonist 321 defining 438-439 Bonsentan 180-181
structure 322 Appetite disorders, corticotrophin- Borate dipyrromethene (BODIPY) in
cAMP releasing factor and 169 fluorescent ligand studies 394-399
B, agonist (long-acting) effects 327-328 Arachidony] ethanolamide 201 (BR) Bowery, Norman 124
opioid-stimulated formation 265 ARL67085 388 BQ123 180
phosphodiesterase 4 regulation in Arrestins, characteristics 417 Brain
inflammatory and immunocompetent Arrhythmias blood pressure regulation and the
cells by 332 adenosine effects 141 358-359
prostacyclin receptors and 17 researcher's studies of 53, 54 catecholamines and effects of SSRI
cAMP phosphodiesterase type 4 Arthritis, corticotrophin-releasing on uptake by 150-152, 400-402 (L)
294-298, 331-336 factor and 170 corticotrophin-releasing factor and
B,-agonist tolerance in asthma and Association of the British Pharmaceutical CRF receptors 168-169, 170, 171
331-336 Industry infarction, pathophysiology 227-228
phosphorylation 295, 333-334 Asthma ischaemic, see Ischaemia
subtypes 294-298 contract research pharmacology melatonin receptors
chromosomal localization and genomic inflammation in, see Inflammation see also Central nervous system
organization 294 kinins / tachykinins (and their BRC672
differential splicing 295 antagonists) in 258-259 Brown adipose tissue, B;-adrenoceptors
distribution and expression 296-297 phosphodiesterase 4 and 8,-agonist and
enzyme activity 295 tolerance in 331-336 BSc, see Pharmacology education
molecular structure 295, 295-296 Atherosclerosis, endothelin and 179
rolipram binding, high-affinity 296 Atopic disease, phosphodiesterase 4 Cc
selective inhibition 297-298 upregulation 334-335 CACA and GABA, receptors 319, 321
transcriptional regulation and ATP, P, purinoceptors and 387-388 Cachexia of cancer and ubiquitin-
phosphorylation 295 ATP-binding cassette proteins 273-275 dependent proteolysis in skeletal
AMPA receptors and amyotrophic lateral ATP-dependent actin—myosin interaction, muscle 224
sclerosis 116 myosin light chain kinase involvement Caffeine
Amphotericin B 445-449 in 273-275 adenosine receptors and 108, 369
mechanism of action 445, 447-448 ATP-sensitive K+ channels, pancreatic, chronic administration 108
new delivery systems 445-446 sulphonylurea receptor as regulator Calcitonin gene-related peptide and
non-fungal pathogens responding to of 273-274, 275 vestibulo—ocular reflex 423
446-447 Atropine and detrusor function 162 Calcium ion(s)
toxicity 445, 446, 448 Auditory processes, ATP and 388 actin-binding proteins and 284-287
Amyotrophic lateral sclerosis 114-120 Australia, pharmacology careers 34-36 intracellular
Anaesthetics and 5-HT, amyotrophic lateral sclerosis and 118
receptors 96, 97-99 B opioid-induced increases 265, 267
Anandamide 201 (BR) Baclofen, spinal cord effects 459-460 Calcium ion channel blockers in stroke 231
Angiotensin II receptor Beart, Philip M. 124 Caldesmon and actin-myosin
type 1 (AT,), ligand binding site 135-140 Behavioural effects of caffeine (chronic interactions 285-286
type 2 (AT,), antagonists 136 administration) 108-110 Calmodulin in actin-myosin
Angiotensin-converting enzyme as a Behavioural Pharmacology 66 (SR) interactions 284, 285
neuropeptidase 291 Benzamides and benzimidazolone effects of inhibitors 286
Annual Review ofM edicine: Selected Topics in derivatives, detrusor muscle effects 314 Calponin and actin-myosin
the Clinical Sciences 270 (BR) Benzodiazepines 192-199 interactions 286
Annual Review of Pharmacology and safer 196-199 Cancer cachexia and ubiquitin-dependent
Toxicology (Vol. 36) 299 (BR) research strategies to obtain 196-197 proteolysis in skeletal muscle 224
Annual Review of Physiology 269 (BR) therapeutic use, drawbacks 193-196 Cannabinoid Receptors 201 (BR)
Antiarrhythmic drugs, researcher's studies Beta-adrenoceptors, see Adrenoceptors Capsaicin ablation of airway sensory
of 53, 54 Betaseron 452 neurones 255
Antibodies BIBP3226 301-302, 436 2-(Carboxycyclopropyl)glycine
to extracellular loops of seven affinity for neuropeptide Y receptors 302 analogues 430
transmembrane domain receptors, structure 302 4-Carboxyphenylglycine 431
receptor activation by 214-215 vascular effects 303-304 Cardiovascular system
monoclonal, therapeutic applications BIBP3435 302 disease, endothelin and 179-180
450, 453-454 affinity for neuropeptide Y receptors 302 neurotransmitters (and their receptors)
Anticholinesterases, dementia subtypes vascular effects 303 regulating 253, 356-363, 385-386
defined by response to 155-160 Bicuculline-insensitive GABA; receptors see also Heart; Vasculature
Anticoagulants in stroke 229, 231 322 Careers, see Pharmacology careers
Anticonvulsant drugs Biomedical multimedia software 66 (SR) Catecholamine(s)
adenosine and 143-144 UK, personal accounts 55-57, 62, 63 Deconvolution methods
cardiovascular system and 356-360 training, Germany 48 Degrees in pharmacology, see
as ‘keys’ for adrenoceptors 213-214 Clinical trials, clinical pharmacologists’ Pharmacology
neuropsychiatric disorders and 132-134 roles 46 education/ training /d egree courses
receptors Clonidine, structure 14 Delivery systems, drug, for
ligand binding, energetics 238-244 Co-agonism in drug-receptor amphotericin B 445-446
vestibulo—ocular reflex and 424-425 interactions 220-222 5-opioid receptor 234 (BR)
SSRI effects on uptake of Cocaine withdrawal 260-264 Dementia subtypes defined by response
150-152, 400-402 (L) Coenzyme Q,, in Huntington’s disease to anticholinesterases 155-160
see also Amines; Monoamine and specific treatment 339 see also specific types of diseases/dementia
catecholamines/catecholamine receptors Cognition Dependence liability with
Catecholaminergic innervation of adenosine receptor ligand effects, acute benzodiazepines, lack, with
neocortex, opioid receptors and 411 vs. chronic 111 imidazenil 198
Cations benzodiazepine adverse effects Depression
GABA-activated Cl current- 193-194, 198-199 bipolar (manic-depressive illness),
modulating 322 imidazenil lacking 198-199 tyrosine hydroxylase and 132-133
5-HT; receptor-modulating 99 Colon, neuropeptide Y receptors 436 corticotrophin-releasing factorand 169
Caudal ventrolateral medulla and Companion to Pharmacology (2nd edn) Dermatitis, atopic, phosphodiesterase
cardiovascular regulation 362 174 (BR) 4 upregulation 334
Caveolin and caveolae 92 Conference management 65 Design, drug, molecular modelling in
CC chemokines 209 Contract research pharmacology 60-61 463 (BR)
receptors 210-211 Contraction, smooth muscle, see Smooth Detrusor muscle
CCG analogues 430 muscle contraction 162
Cell Corticosteroid (synthetic), treatment agents reducing contractility
death, programmed, see Apoptosis 148-149 162-164, 164-165, 314-316 (L)
membranes, see Membranes Corticosteroid receptors control, 161-162
signalling, protease-mediated 3-6 gene activation by 146-147 innervation 161-162
Central nervous system heterodimerization increasing functional Dihydropyrimidinase deficiency 106
adenosine A, antagonist effects 368, 371 diversity of corticosteroid Dihydropyrimidine dehydrogenase
adrenoceptors, see Adrenoceptors action 145-149 deficiency 106 (L), 107 (L)
cardiovascular homeostasis and clinical implications 148-149 metabolism 106 (L)
253, 356-363 pharmacology 145 Divaplon 197
disorders, see Neurological disease Corticotrophin (ACTH)-releasing factor, Dizocilpine in stroke 229
ectoenzyme-mediated neuropeptide in CNS disorders DMPX 386
metabolism 288-294 high levels, treatment 171 DNA transcription factors,
nitrergic neurotransmission 207 low levels, treatment 171-172 glucocorticoid / mineralocorticoid
pyrimidines and 106-107 (L) role 169-170 receptor heterodimers interacting
see also specific regions Corticotrophin (ACTH)-releasing factor with other 147-148
Cerebral cortex receptors 166-172 Dollery, Professor Sir Colin, Festschrift
ischaemia, see Ischaemia subtypes 166-167 in honour of 317-318
morphine addiction and 414 localization 168-169 L-DOPA, see Levodopa
Cerebrovascular accident, see Stroke nomenclature 168 Dopamine
CGP12177 394, 399 Corticotrophin (ACTH)-releasing receptors
CGP35348 460 factor-binding protein 167-168 adenosine A,, receptor interactions
CGS15943 369, 370 localization 169 366-367
CGS20625 197 pharmacology 167-168 caffeine and theophylline targeting 110
CGS21680 365, 366, 369, 370, 371, 386 structure 167 ligand binding, energetics 238-244
CGS26303 177-178 Co-transmission in nitrergic nerves 205-207 vestibulo—ocular reflex and 424
Chemokines 209-213 CP15943 370 replacement therapy, Parkinson’s
receptors 209-213 CP66713 370 disease 133, 339
cloning / characterization 209-213 CP96345 256 SSRI effects on uptake of 150, 151, 401 (L)
in disease 212 CP99994 258 Dopaminergic system
types 209 CPCCCOEt 431 cocaine withdrawal and 260-263
Chemotactic Methods in Molecular 4CPG 431 in Lewy-body disease, drugs aimed
Design 28 (BR) RS-CPPG 432 at 159, 160
Chloride channels Crawley, Jacqueline 124 morphine administration and its
ABC proteins regulating 273 Cuello, A. Claudio 125 effects 410-411, 413
GABA-gated 319-320, 322 CXC chemokines 209 Dorsal root ganglion
benzodiazepine action on 194-195 receptors 209-210 adrenoceptors in 252-253
8-(3-Chlorostyryl)caffeine in cerebral Cyclic nucleotides opioid stimulatory effects 264-265
ischaemia 112 receptor 308 DPCPX 367, 369
Cholecystokinin and its peptide specific, see AMP; GMP DPMTX 367, 369
fragments, bioactivity 291 Cyclopropan[b]chromen-1la-carboxylate Drug
Choline acetyltransferase (ChAT) abuse, cocaine withdrawal 260-264
gene 131-132 (RS)-a-Cyclopropyl-4- clinical research 463-464 (BR)
Cholinergic transmission phosphonophenylglycine delivery systems for amphotericin B
enhancement/ potentiation, Cys-loop superfamily of receptors 445-446
strategies 155-157, 159 Cysteinyl leukotriene receptors in lung design, molecular modelling 463 (BR)
in Lewy-body dementia 158 342-345 Duffy antigen receptor 209, 211
drug treatment aimed at 159, 160 Cystic fibrosis transmembrane malaria and 212
morphine effects 412 conductance regulator 273, 308 Dynorphin, peptide fragment derived
in voiding disorders 314 drug targeting 274-275 from, and its bioactivity 290
Cholinesterase inhibitors and dementia structure 274 Dyskinesias, levodopa-induced, neuronal
subtypes 155-160 Cytochrome P450 174 (BR) mechanisms 340-342
Cicaprost, structure 18 SSRI effects on 154 Dysrhythmias, see Arrhythmias
Cirazoline, structure 14 Cytokines in phosphodiesterase 4
Circadian rhythms and melatonin 100, 102 regulation 332 E
Clinical drug research 463-464 (BR) Cytomegalovirus, chemokine receptor Eating disorders, corticotrophin-
Clinical pharmacology gene 211 releasing factor and 169
careers Ectoenzyme-mediated neuropeptide
Germany 4849 D metabolism 288-294
Japan 45-47 ‘Death’ receptors EDRF, see Nitric oxide
Education, see Pharmacology education Freelance medical writing from reporter, in G protein-coupled receptor
Electrolyte homeostasis, home agonist screening 236-237
neuropeptide Y and peptide YY see also specific genes
involvement 436-438 G Gene therapy 450-451, 454-455
Electrostatic catecholamine G protein(s) Parkinson’s disease 133-134
receptor-ligand interactions 240-242 G protein-coupled receptor interactions General anaesthetics and 5-HT,
Emerging Drugs (Vol. 1) 337 (BR) with 91-92 receptors 96, 97-99
B-Endorphin, ectoenzyme-mediated phospholipase D activity and 182 Genetic polymorphisms, hepatic drug
metabolism leading to peptide universal adapter, G,, as a 235-237 metabolism and 46
fragments (and their bioactivity) G protein-coupled receptor(s) 416-421 Genome, human, 5-HT,, and 5-HT,p
290, 292-293 agonists, screening system 235-237 subtype classification and the 103-105
neuroleptic-induced alterations 292-293 B,-adrenoceptors as 375-376 Germany, pharmacology careers 47-49
Endothelin 177-181 desensitization Globus pallidus (GP) and Parkinson’s
mechanisms and regulation of 177 heterologous disease 339-340
pathophysiology 179-180 homologous Glucocorticoid receptors
Endothelin receptors 178-179 GTP effects effects mediated in vivo 145-146
antagonists 178-179 interactions with G proteins heterodimerization with
chemistry 178-179 promiscuity mineralocorticoid receptors increasing
clinical studies 180-181 melatonin receptors as functional diversity of corticosteroid
structures 178 two-state model action, see Corticosteroid receptors
Endothelin-converting enzymes 177-178 G protein-coupled receptor kinases 417-420 pharmacology 145
inhibitors 177 characteristics 416 Glutamate
Endothelium gene expression and activity, cardiovascular regulation and 361-362
leukotriene receptors 344 regulation 418-419 glycine and, co-agonism at NMDA
NO (endothelium-derived relaxing receptors phosphorylated by 417 receptors 220-222
factor) and NO synthase, see Nitric GABA 457-462 metabotropic Glu receptors regulating
oxide; Nitric oxide synthase cardiovascular regulation involving 359 release of 432-433
Energy metabolism and chloride channels gated by, see Chloride morphine administration and its
B,-adrenoceptors channels effects 412, 413
Enteric nervous system, nitrergic morphine administration and its transporters 308
neurotransmission effects 412, 413, 414 vestibulo-ocular reflex and 422
EP157, actions in spinal cord 457-462 Glutamate receptors 429-435
EP185 localization 458 metabotropic 429-435
actions physiology 458-459 drugs for 430-432
structure vestibulo—ocular reflex and 423, 424 ionotropic and, interactions 433-434
Epileptic seizures, adenosine GABA receptors (in general) molecular characterization 429-430
receptor ligands and neuroprotection in spinal cord 457-462 neurodegenerative diseases and
from, acute vs. chronic administration location 457 116, 435
111-112 vestibulo—ocular reflex and 424 signal transduction and 433-434
Erythropoietin 451 GABA, receptors 192, 319, 457 synaptic transmission and role of
Essentials of Pharmacology 203 (BR) agonists/ p artial agonists 320-321 434-435
Ethanol and 5-HT; receptors 95, 96 antagonists 321-322 transmitter release and 432-433
5’-N-Ethylcarboxamide adenosine benzodiazepine ligands for 192-193 stroke therapy aimed at blocking
(NECA) 142, 143 for specific receptor subtypes 196-199 228-230
Excitatory amino acids GABA, receptor properties compared see also specific types
amyotrophic lateral sclerosis and 114-116 with 320 Glycine (and NMDA receptors)
Huntington's disease and 339 GABA¢ receptor as subclass of 323 glutamine co-agonism with 220-222
receptors 306 GABA¢ receptor properties compared subunit-dependent difference in
vestibulo—ocular reflex and 423-424 with 320 binding 351
Exosites and duration of action of redox modulation 186, 188 GMP, cyclic, NO and 207
long-acting B-agonists 324-330 in spinal cord 457-462 Godfraind, Théophile 125
Extracellular fluid in adipose tissue, in situ location 457 Good Laboratory Practice 175 (BR)
microdialysis in measurement of GABA, receptors 319, 457 GR31354 328
substances in 312 properties compared with GR35795 328
GABA, /GABA¢ receptors 320 Graduate education in Canada 36-38
F in spinal cord 457-462 GTP effects on G protein-coupled
Fas-mediated death and chronic antinociception and 460 receptors 189
inflammation 438-442 baclofen effects 459-460 GTPase and «,-adrenoceptors 91
Fat cells, secretory activity 312-313 location 457 Guanabenz, structure 14
8FB-PTP 370 GABA¢ receptors 192, 319-323 Guide to Clinical Drug Research 463-464 (BR)
F,CCG-I 430 GABA, receptor properties compared Guidebook on Molecular Modelling in
Finasteride in benign obstructive with 320 Drug Design 463 (BR)
prostatic hyperplasia 164 as GABA, receptor subclass 323 Gut, see Gastrointestinal tract
FK224 258 GABA, receptor properties compared
FK888 258 with 320 H
Flow cytometry 395 spinal cord 457 Hadden, John 7
FLP55712 343 Gastrointestinal Drug Therapy, Handbook of Halogenated alcohols and 5-HT,
Fluorescent ligands, receptor studies 174 (BR) receptors 95-97
393-399 Gastrointestinal tract Haloperidol,
Fluorinated pyrimidines, neurotoxicity nervous system, nitrergic neuropeptides /neuropeptidases and
106 (L), 107 (L) neurotransmission 207 effects of 292, 293
Fluoxetine 150-154, 400-402 (L) neuropeptide Y and peptide YY Halothane and 5-HT, receptors 96, 97
Food deprivation, ubiquitin-dependent effects 436 Handbook of Gastrointestinal Drug
proteolysis in skeletal muscle 224 Gehrig's disease 114-120 Therapy 174 (BR)
Formeterol 324 Gene(s) Heart
characteristics of duration of action cerebral ischaemia-activated 232 failure
chemokine receptor 212 congestive, endothelins in
Fozard, John R. corticosteroid receptor-activated 146-147 179-180, 180-181
FR139317 novel, mRNA differential display G protein-coupled receptor kinases
Fredholm, Bertil B. 276-279 and arrestins and 419-420
Free radical scavengers in stroke compared with, subtractive library ischaemia, adenosine receptor
therapy screening for discovering 277 antagonists in 371, 385-386